TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1.
Jahn L, Hombrink P, Hagedoorn RS, Kester MG, van der Steen DM, Rodriguez T, Pentcheva-Hoang T, de Ru AH, Schoonakker MP, Meeuwsen MH, Griffioen M, van Veelen PA, Falkenburg JH, Heemskerk MH.
Jahn L, et al. Among authors: schoonakker mp.
Blood. 2017 Mar 9;129(10):1284-1295. doi: 10.1182/blood-2016-09-737536. Epub 2017 Jan 4.
Blood. 2017.
PMID: 28053195
Free article.